These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Progress in targeting RAS with small molecule drugs. McCormick F Biochem J; 2019 Jan; 476(2):365-374. PubMed ID: 30705085 [TBL] [Abstract][Full Text] [Related]
8. Targeting mutated GTPase KRAS in tumor therapies. Fan G; Lou L; Song Z; Zhang X; Xiong XF Eur J Med Chem; 2021 Dec; 226():113816. PubMed ID: 34520956 [TBL] [Abstract][Full Text] [Related]
9. Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation. Winter JJ; Anderson M; Blades K; Brassington C; Breeze AL; Chresta C; Embrey K; Fairley G; Faulder P; Finlay MR; Kettle JG; Nowak T; Overman R; Patel SJ; Perkins P; Spadola L; Tart J; Tucker JA; Wrigley G J Med Chem; 2015 Mar; 58(5):2265-74. PubMed ID: 25695162 [TBL] [Abstract][Full Text] [Related]
10. Drug Discovery by Targeting Mutant KRAS. Ye N Curr Top Med Chem; 2019; 19(23):2079-2080. PubMed ID: 31762422 [No Abstract] [Full Text] [Related]
11. The path to the clinic: a comprehensive review on direct KRAS Kwan AK; Piazza GA; Keeton AB; Leite CA J Exp Clin Cancer Res; 2022 Jan; 41(1):27. PubMed ID: 35045886 [TBL] [Abstract][Full Text] [Related]
12. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors. Stites EC; Shaw AS CPT Pharmacometrics Syst Pharmacol; 2018 May; 7(5):342-351. PubMed ID: 29484842 [TBL] [Abstract][Full Text] [Related]
13. Exploring Targeted Degradation Strategy for Oncogenic KRAS Zeng M; Xiong Y; Safaee N; Nowak RP; Donovan KA; Yuan CJ; Nabet B; Gero TW; Feru F; Li L; Gondi S; Ombelets LJ; Quan C; Jänne PA; Kostic M; Scott DA; Westover KD; Fischer ES; Gray NS Cell Chem Biol; 2020 Jan; 27(1):19-31.e6. PubMed ID: 31883964 [TBL] [Abstract][Full Text] [Related]